Discover
TECX
Tectonic Therapeutic, Inc.
32.74
2 x 24.58
2 x 41.22
bid
ask
-
1.63
4.76%
2 @ 04:00 PM
32.74 +0.00 (0.00%)
| Ytd | 56.95% | |
| 1y | 62.40% |
31.72
day range
34.57
14.39
52 week range
36.03
| Open | 34.13 | Prev Close | 34.38 | Low | 31.72 | High | 34.57 | Mkt Cap | 617.78M |
| Vol | 228.62K | Avg Vol | 196.73K | EPS | -4.46 | P/E | N/A | Forward P/E | -10.16 |
| Beta | N/A | Short Ratio | 3.54 | Inst. Own | 46.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 29.29 | 200-d Avg | 23.65 | 1yr Est | 74.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.84 | -1.2 | -0.36 | -42.86% |
| 2024-08-14 | 2024-06 | -1.96 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -1.96 | -3.81 | -1.85 | -94.39% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-20 | Raymond James | Upgrade | Outperform | |
| 2024-11-12 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2024-11-11 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2024-08-22 | Wells Fargo | Upgrade | Overweight | |
| 2024-07-24 | Leerink Partners | Upgrade | Outperform | |
| 2024-06-26 | Piper Sandler | Upgrade | Overweight |
Profile
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-19 | CORTIS CHRISTIAN | Chief Operating Officer | 126.37K | Stock Award(Grant) |
| 2024-05-13 | LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-06-19 | MCGUIRE TERRANCE G | Director | 0.00 | Stock Award(Grant) |
| 2024-12-02 | MCNAMARA PETER | Officer | 14.19K | Conversion of Exercise of derivative security |
| 2024-12-03 | REICIN ALISE S | Chief Executive Officer | 302.83K | Stock Award(Grant) |
| 2024-06-19 | RUDDY MARCELLA KUHLMAN M.D. | Officer | 32.07K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 1.22M | 58.03M | 8.27% |
| 2024-09-29 | Vida Ventures Advisors, LLC | 1.03M | 48.92M | 6.97% |
| 2024-09-29 | EcoR1 Capital, LLC | 849.14K | 40.39M | 5.76% |
| 2024-09-29 | 5AM Venture Management, LLC | 646.52K | 30.75M | 4.38% |
| 2024-09-29 | Farallon Capital Management LLC | 520.40K | 24.75M | 3.53% |
| 2024-09-29 | Vanguard Group Inc | 442.81K | 21.06M | 3.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 381.59K | 18.15M | 2.59% |
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 142.60K | 6.78M | 0.97% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 44.79K | 2.13M | 0.30% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 38.23K | 1.82M | 0.26% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 18.95K | 901.17K | 0.13% |
| 2024-10-30 | iShares Micro Cap ETF | 18.56K | 882.90K | 0.13% |